France· FR:62801026
PIQRAY 50 mg et 200 mg, comprimé pelliculé
A medicinal product containing alpélisib, registered in France by NOVARTIS EUROPHARM (IRLANDE).
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- ALPÉLISIB
- Manufacturer
- NOVARTIS EUROPHARM (IRLANDE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009302103212 plaquettes PVC polychlortrifluoroéthylène aluminium de 14 comprimés de 50 mg- 2 plaquettes PVC polychlortrifluoroéthylène aluminium de 14 comprimés de 200 mg
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Alpélisib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwedenPiqray 50 mg + 200 mg Filmdragerad tablettNovartis Europharm Limited
- BelgiumPiqray 50 mg - 200 mgNovartis Europharm
- NetherlandsPiqray 50 mg filmomhulde tablettenNovartis Europharm Limited
- FinlandVijoiceNovartis Europharm Limited
- IrelandPiqray 50 mg film-coated tablets Piqray 200 mg film-coated tabletsNovartis Europharm Limited
- CzechiaVIJOICENovartis Europharm Limited, Dublin
- NorwayPiqrayNovartis Europharm Limited (1)
- PolandVijoiceNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Piqray, Vijoice
- Liechtenstein · Piqray, Vijoice
- Norway · Piqray, Vijoice
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2227df78-325d-41b1-8691-3e6abdf57572 GET /v1/drugs/2227df78-325d-41b1-8691-3e6abdf57572?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "62801026",
"date_amm": "2020-07-27",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/20/1455",
"substance": "ALPÉLISIB",
"statut_amm": "Autorisation active",
"statut_bdm": "Warning disponibilité",
"forme_pharmaceutique": "comprimé pelliculé et comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Non commercialisée",
"surveillance_renforcee": "Non"
}See everything about alpélisib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.